CVR

Future Pak Issues Enhanced and Final Proposal to Acquire Vanda Pharmaceuticals Inc.

Retrieved on: 
木曜日, 6月 13, 2024
Research, Packaging, Fitness & Nutrition, Manufacturing, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, Pak, PDUFA, CVR, FDA, Calendar, Sale, Pharmaceutical industry

Future Pak, LLC and its affiliates ("Future Pak") today announced that it has submitted a final attempt to engage with Vanda Pharmaceuticals Inc. ("Vanda" or the "Company") in a good faith effort to acquire all outstanding shares of Vanda (the “Transaction”).

Key Points: 
  • Future Pak, LLC and its affiliates ("Future Pak") today announced that it has submitted a final attempt to engage with Vanda Pharmaceuticals Inc. ("Vanda" or the "Company") in a good faith effort to acquire all outstanding shares of Vanda (the “Transaction”).
  • “We are not surprised that other parties see similar opportunities at Vanda as we do,” stated Tina Guilder, Head of Transactions at Future Pak.
  • Our revised proposal is a final attempt at delivering value to Vanda shareholders far in excess of what the market indicates Vanda can achieve on a standalone basis.
  • Future Pak encourages Vanda shareholders to contact the Company to support engagement with Future Pak on this Final Proposal by June 26, 2024, and to launch a formal review of strategic alternatives (including a sale of the Company).

Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
木曜日, 5月 9, 2024
CVR, CHRS, FDA, GAAP, TSA, Total, NCCN, Investment, Ophthalmology, Conference call, Research, CRI, Conference, ADCC, Exercise, Cancer Research Institute, Medicare Advantage, Acquisition, NPC, Medicare, COGS, Ovarian cancer, Relative value unit, Pharmaceutical industry

REDWOOD CITY, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today reported financial results for the quarter ended March 31, 2024 and recent business highlights: 

Key Points: 
  • Total unit demand grew 36% in Q1 2024 compared to Q4 2023 and represented a 108% increase compared to Q1 2023.
  • Based on data from IQVIA, UDENYCA franchise market share for Q1 2024 was 25%, an increase of 10 market share points in Q1 2024 compared to Q4 2023.
  • LOQTORZI, the first and only FDA-approved treatment for recurrent, locally advanced or metastatic NPC, commercially launched on January 2, 2024.
  • Coherus projects combined R&D and SG&A expenses for 2024 to be in the range of $250 to $265 million.

Pineapple Energy Reports First Quarter 2024 Financial Results

Retrieved on: 
木曜日, 5月 9, 2024
CVR, Pineapple, Marketing, Webcast, Investment, CSI, Earnout

MINNETONKA, Minn., May 09, 2024 (GLOBE NEWSWIRE) -- Pineapple Energy Inc. (NASDAQ: PEGY), a leading provider of sustainable solar energy and back-up power to households and small businesses, today announced financial results for the first quarter ended March 31, 2024.

Key Points: 
  • Total revenue was $13.2 million in the first quarter of 2024, down $8.8 million, or 40%, from the first quarter of 2023.
  • Gross margin remained flat at 36% during the first quarter of 2024 as compared to the first quarter of 2023.
  • Other income (expense) was $3.4 million in the first quarter of 2024, an increase of $3.8 million, from the first quarter of 2023.
  • As announced on May 6, 2024, Pineapple will discuss its first fiscal quarter results via a webcast and conference call on Friday, May 10, 2024 at 08:30 a.m.

XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities

Retrieved on: 
木曜日, 5月 9, 2024
Cream, CVR, Sale, FDA, BRAF V600, Organon, NDA, Food, Compugen, Department of Defence, Economics, Female, BRAF, PDUFA, Blue Owl Capital, Patient, Bayer, Acquisition, Share repurchase, Food and Drug Administration, Defense, Pharmaceutical industry

EMERYVILLE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, reported its first quarter 2024 financial results and highlighted recent activities.

Key Points: 
  • Earned $9 million milestone upon U.S. Food and Drug Administration’s approval of Day One’s OJEMDA™ (tovorafenib);
    EMERYVILLE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, reported its first quarter 2024 financial results and highlighted recent activities.
  • XOMA receives 100 percent of the DSUVIA® economics until a threshold is achieved; thereafter, XOMA retains the 15 percent royalty associated with DSUVIA® commercial sales.
  • The 75 percent royalties from Department of Defense purchases and remaining milestone payments will be shared equally between XOMA and Talphera.
  • Dosed first patient in its Phase 3 trial of RZ358; XOMA earned a $5.0 million milestone associated with the event.

Future Pak Increases Bid for Vanda Pharmaceuticals to Include CVRs in Addition to $7.25 to $7.75 Per Share in Cash

Retrieved on: 
火曜日, 5月 7, 2024
Biotechnology, Pharmaceutical, Finance, Health, Packaging, Professional Services, Fitness & Nutrition, Manufacturing, Proposal, CVR, FDA, LLP, Honigman LLP, Contingent value rights, PDUFA, Pak, Calendar, Pharmaceutical industry

“In an effort to make progress, we have again increased our consideration for Vanda to provide a potential framework for CVRs that could bring total consideration significantly higher.

Key Points: 
  • “In an effort to make progress, we have again increased our consideration for Vanda to provide a potential framework for CVRs that could bring total consideration significantly higher.
  • This increase comes despite the uncertainty of further cash burn in the coming quarters,” stated Tina Guilder, Head of Transactions of Future Pak.
  • Despite multiple actions by Vanda to limit stockholder influence, Future Pak remains staunchly committed to consummating a transaction with Vanda.
  • Future Pak has engaged Moelis & Company LLC as financial advisor, Honigman LLP as legal advisor, and MacKenzie Partners, Inc. as investor engagement advisor.

SES to acquire Intelsat: Investor Relations Frequently Asked Questions

Retrieved on: 
月曜日, 5月 6, 2024
Networks, Satellite, Audio, Video, Technology, Telecommunications, CVR, Sale, Prospectus, International, Contingent value rights, Risk, ASC, Communication, Metric, Form, Intelsat, Cropping system, Hertz, BBB, Adjustment, WHEN, FX, Capital expenditure, GAAP, Overalls, F-4, C band, Security (finance)

SES expects most of these contracts to be renewed during the coming years resulting in continued stream of cash generating revenue and EBITDA.

Key Points: 
  • SES expects most of these contracts to be renewed during the coming years resulting in continued stream of cash generating revenue and EBITDA.
  • In January 2024, SES repaid its €550 million hybrid bond with cash, reducing SES gross debt to €3.6 billion.
  • In connection with the proposed transaction, SES intends to file with the SEC a registration statement on Form F-4 that also constitutes a prospectus of SES.
  • Copies of the documents filed with the SEC by SES will be available free of charge on SES’s website at www.ses.com or by contacting SES’s Investor Relations Department by email at [email protected] .

TAKE ACTION: The M&A Class Action Firm Launches Legal Inquiry for the Merger - ALPN, LABP, SWAV, FUSN

Retrieved on: 
月曜日, 4月 22, 2024
CVR, Vertex Pharmaceuticals, Sale, ALPN, AbbVie, Johnson & Johnson, Empire, AstraZeneca, Security (finance)

Under the terms of the agreement, ALPN shareholders are expected to receive $65.00 in cash per share they own.

Key Points: 
  • Under the terms of the agreement, ALPN shareholders are expected to receive $65.00 in cash per share they own.
  • It is free and there is no cost or obligation to you.
  • Under the terms of the agreement, SWAV shareholders are expected to receive $335.00 in cash per share they own.
  • Before you hire a law firm, you should talk to a lawyer and ask:
    Do you file class actions and go to Court?

CVR Partners to Release First Quarter 2024 Earnings Results

Retrieved on: 
火曜日, 4月 16, 2024
CVR Partners, CVR, Partnership, Ammonia, Webcast, UAN

SUGAR LAND, Texas, April 16, 2024 (GLOBE NEWSWIRE) -- CVR Partners, LP (NYSE: UAN), a manufacturer of ammonia and urea ammonium nitrate (UAN) solution fertilizer products, plans to release its first quarter 2024 earnings results on Monday, April 29, after the close of trading on the New York Stock Exchange.

Key Points: 
  • SUGAR LAND, Texas, April 16, 2024 (GLOBE NEWSWIRE) -- CVR Partners, LP (NYSE: UAN), a manufacturer of ammonia and urea ammonium nitrate (UAN) solution fertilizer products, plans to release its first quarter 2024 earnings results on Monday, April 29, after the close of trading on the New York Stock Exchange.
  • The Partnership also will host a teleconference call on Tuesday, April 30, at 11 a.m. Eastern to discuss these results.
  • This call, which will contain forward-looking information, will be webcast live and can be accessed on the Investor Relations section of CVR Partners’ website at www.CVRPartners.com .
  • A repeat of the call also can be accessed for 14 days by dialing (877) 660-6853, conference ID 13745529.

CVR Energy to Release First Quarter 2024 Earnings Results

Retrieved on: 
火曜日, 4月 16, 2024
CVR, CVI, Webcast

SUGAR LAND, Texas, April 16, 2024 (GLOBE NEWSWIRE) -- CVR Energy, Inc. (NYSE: CVI) plans to release its first quarter 2024 earnings results on Monday, April 29, after the close of trading on the New York Stock Exchange.

Key Points: 
  • SUGAR LAND, Texas, April 16, 2024 (GLOBE NEWSWIRE) -- CVR Energy, Inc. (NYSE: CVI) plans to release its first quarter 2024 earnings results on Monday, April 29, after the close of trading on the New York Stock Exchange.
  • The Company also will host a teleconference call on Tuesday, April 30, at 1 p.m. Eastern to discuss these results.
  • This call, which will contain forward-looking information, will be webcast live and can be accessed on the Investor Relations section of CVR Energy’s website at www.CVREnergy.com .
  • A repeat of the call also can be accessed for 14 days by dialing (877) 660-6853, conference ID 13745530.

STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – DOMA, LABP, FUSN, CBNK

Retrieved on: 
火曜日, 4月 9, 2024
AbbVie, Empire, AstraZeneca, Integration, Sale, Capital, DOMA, CBNK, CVR, Security (finance)

NEW YORK, April 09, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report.

Key Points: 
  • NEW YORK, April 09, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report.
  • Under the terms of the agreement, DOMA shareholders are expected to receive $6.29 in cash per share they own.
  • Capital Bancorp, Inc. (Nasdaq: CBNK ), relating to its proposed merger with Integrated Financial Holdings, Inc.
  • Under the terms of the agreement, CBNK shareholders are estimated to receive $5.36 in cash and 1.115 shares of Capital common stock per share they own.